Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorhexidine Solutions for VAP Prevention
NCT06733090Active, not recruiting
- Start
- Oct 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of chlorhexidine in ventilator-associated pneumonia (VAP) (2 arms). Primary endpoints: Acute Physiology and Chronic Health Evaluation II at 24 hours, Follow-up period of patients checklist up to 30 days and 3 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
chlorhexidine
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT06733090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06733090.